Tenax Therapeutics Stock Price, News & Analysis (NASDAQ:TENX)

$0.41 0.02 (5.13 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$0.41
Today's Range$0.38 - $0.42
52-Week Range$0.31 - $2.65
Volume95,522 shs
Average Volume759,543 shs
Market Capitalization$11.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95

About Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics logoTenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:TENX
  • CUSIP: N/A
  • Web: www.tenaxthera.com
Debt:
  • Current Ratio: 10.43%
  • Quick Ratio: 4.12%
Sales & Book Value:
  • Annual Sales: $40,000.00
  • Price / Sales: 289.46
  • Book Value: $0.36 per share
  • Price / Book: 1.14
Profitability:
  • Trailing EPS: ($1.32)
  • Net Income: ($43,920,000.00)
  • Return on Equity: -89.80%
  • Return on Assets: -70.67%
Misc:
  • Employees: 11
  • Outstanding Shares: 28,240,000
 

Frequently Asked Questions for Tenax Therapeutics (NASDAQ:TENX)

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings data on Tuesday, December, 15th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. View Tenax Therapeutics' Earnings History.

Where is Tenax Therapeutics' stock going? Where will Tenax Therapeutics' stock price be in 2017?

1 brokers have issued 12-month price objectives for Tenax Therapeutics' shares. Their predictions range from $2.50 to $2.50. On average, they expect Tenax Therapeutics' stock price to reach $2.50 in the next twelve months. View Analyst Ratings for Tenax Therapeutics.

Who are some of Tenax Therapeutics' key competitors?

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the folowing people:

  • Ronald R. Blanck, Independent Chairman of the Board (Age 74)
  • Michael B. Jebsen CPA, President, Interim Chief Executive Officer, Chief Financial Officer (Age 44)
  • Douglas Hay Ph.D., Executive Vice President - Regulatory Affairs
  • Doug Randall, Executive Vice President - Business and Commercial Operations
  • Paula Bokesch, Chief Medical Officer
  • James Mitchum, Director (Age 62)
  • Gerald T. Proehl, Director (Age 58)
  • Anthony DiTonno, Independent Director (Age 68)
  • Gregory Pepin, Independent Director (Age 32)
  • Chris A. Rallis, Independent Director (Age 61)

Who owns Tenax Therapeutics stock?

Tenax Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Financial Advisory Service Inc. (4.58%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.

Who bought Tenax Therapeutics stock? Who is buying Tenax Therapeutics stock?

Tenax Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Financial Advisory Service Inc.. Company insiders that have bought Tenax Therapeutics stock in the last two years include Gerald T Proehl and Ronald R Blanck. View Insider Buying and Selling for Tenax Therapeutics.

How do I buy Tenax Therapeutics stock?

Shares of Tenax Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tenax Therapeutics' stock price today?

One share of Tenax Therapeutics stock can currently be purchased for approximately $0.41.

How big of a company is Tenax Therapeutics?

Tenax Therapeutics has a market capitalization of $11.58 million and generates $40,000.00 in revenue each year. The specialty pharmaceutical company earns ($43,920,000.00) in net income (profit) each year or ($1.32) on an earnings per share basis. Tenax Therapeutics employs 11 workers across the globe.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is 1 Copley Pkwy Ste 490, MORRISVILLE, NC 27560-9693, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8064414 or via email at [email protected]


MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Tenax Therapeutics (NASDAQ:TENX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (509.76% upside)

Consensus Price Target History for Tenax Therapeutics (NASDAQ:TENX)

Price Target History for Tenax Therapeutics (NASDAQ:TENX)

Analysts' Ratings History for Tenax Therapeutics (NASDAQ:TENX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$2.50HighView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Tenax Therapeutics (NASDAQ:TENX)

Earnings by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Earnings History by Quarter for Tenax Therapeutics (NASDAQ TENX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.17)($0.15)ViewListenView Earnings Details
12/15/2015Q216($0.14)($0.13)ViewListenView Earnings Details
9/14/2015Q116($0.14)($0.11)ViewListenView Earnings Details
7/16/2015Q415($0.14)($0.18)ViewListenView Earnings Details
3/18/2015Q315($0.16)($0.10)ViewN/AView Earnings Details
12/17/2014Q215($0.18)($0.14)ViewN/AView Earnings Details
3/17/2014($0.38)($0.13)$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tenax Therapeutics (NASDAQ:TENX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.09)($0.09)($0.09)
Q3 20171($0.04)($0.04)($0.04)
Q4 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tenax Therapeutics (NASDAQ:TENX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tenax Therapeutics (NASDAQ TENX)

Insider Ownership Percentage: 9.81%
Institutional Ownership Percentage: 11.06%
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ:TENX)
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Insider Trades by Quarter for Tenax Therapeutics (NASDAQ TENX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Gerald T ProehlDirectorBuy29,882$1.67$49,902.94View SEC Filing  
11/19/2015Ronald R BlanckDirectorBuy4,700$3.26$15,322.00View SEC Filing  
1/20/2015Ronald R BlanckDirectorBuy2,000$3.49$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tenax Therapeutics (NASDAQ:TENX)

Latest Headlines for Tenax Therapeutics (NASDAQ TENX)

Source:
DateHeadline
How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax TherapeuticsHow These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - August 4 at 8:54 AM
TENX: FDA Response on LevosimendanTENX: FDA Response on Levosimendan
finance.yahoo.com - August 3 at 7:52 AM
Tenax Therapeutics Provides Regulatory Update on LevosimendanTenax Therapeutics Provides Regulatory Update on Levosimendan
finance.yahoo.com - July 29 at 7:50 AM
Tenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA SubmissionTenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA Submission
www.streetinsider.com - May 16 at 8:10 PM
Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO ResignsTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns
www.streetinsider.com - April 7 at 11:21 PM
Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.comTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.com
www.streetinsider.com - April 7 at 12:58 PM
Tenax Therapeutics (TENX) Offers FY16 Results, Corporate UpdateTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update
www.streetinsider.com - March 22 at 12:57 AM
BUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - NasdaqBUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - Nasdaq
www.nasdaq.com - March 21 at 7:54 PM
Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.comTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.com
www.streetinsider.com - March 21 at 7:54 PM
Q4 2016 Tenax Therapeutics Inc Earnings Release - Before Market OpenQ4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 21 at 9:57 AM
TENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StTENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
biz.yahoo.com - March 17 at 8:13 PM
TENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportTENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 9:13 PM
Tenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT NewsTenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT News
www.rttnews.com - February 3 at 6:11 AM
Tenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study NewsTenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study News
www.rttnews.com - February 2 at 5:55 AM
9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)
us.rd.yahoo.com - February 2 at 5:55 AM
Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac SurgeryTenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
us.rd.yahoo.com - February 2 at 5:55 AM
Tenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.comTenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.com
www.streetinsider.com - February 1 at 6:52 AM
Tenax Therapeutics: Will It Or Wont It?Tenax Therapeutics: Will It Or Won't It?
www.rttnews.com - January 30 at 11:29 AM

Social Media

Financials

Chart

Tenax Therapeutics (NASDAQ TENX) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.